Concepts (271)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 32 | 2024 | 388 | 5.390 |
Why?
|
| Infectious Disease Transmission, Vertical | 3 | 2013 | 25 | 0.980 |
Why?
|
| Breast Feeding | 3 | 2013 | 43 | 0.960 |
Why?
|
| Data Interpretation, Statistical | 2 | 2013 | 110 | 0.850 |
Why?
|
| Humans | 67 | 2024 | 32297 | 0.830 |
Why?
|
| Sexually Transmitted Diseases | 4 | 2023 | 42 | 0.780 |
Why?
|
| Rural Population | 3 | 2024 | 274 | 0.750 |
Why?
|
| Female | 48 | 2024 | 20126 | 0.740 |
Why?
|
| Accidental Falls | 3 | 2017 | 219 | 0.740 |
Why?
|
| United Nations | 1 | 2020 | 4 | 0.720 |
Why?
|
| Statistics as Topic | 1 | 2020 | 110 | 0.690 |
Why?
|
| Electronic Health Records | 3 | 2017 | 158 | 0.690 |
Why?
|
| Anti-HIV Agents | 4 | 2022 | 54 | 0.660 |
Why?
|
| Guideline Adherence | 1 | 2018 | 122 | 0.600 |
Why?
|
| Male | 41 | 2024 | 19488 | 0.590 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2016 | 9 | 0.570 |
Why?
|
| Pharmacists | 1 | 2016 | 20 | 0.560 |
Why?
|
| Water Pollutants, Chemical | 1 | 2016 | 4 | 0.550 |
Why?
|
| Fluorocarbons | 1 | 2016 | 21 | 0.550 |
Why?
|
| Family Practice | 1 | 2016 | 51 | 0.550 |
Why?
|
| Internal Medicine | 1 | 2016 | 54 | 0.550 |
Why?
|
| Trauma Centers | 4 | 2017 | 94 | 0.530 |
Why?
|
| Islets of Langerhans | 1 | 2016 | 76 | 0.520 |
Why?
|
| HIV-1 | 2 | 2012 | 46 | 0.520 |
Why?
|
| Simian immunodeficiency virus | 1 | 2015 | 1 | 0.510 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 2015 | 1 | 0.510 |
Why?
|
| AIDS Vaccines | 1 | 2015 | 2 | 0.510 |
Why?
|
| Geriatric Assessment | 1 | 2017 | 395 | 0.500 |
Why?
|
| Hospice Care | 1 | 2015 | 13 | 0.500 |
Why?
|
| Terminal Care | 1 | 2015 | 24 | 0.500 |
Why?
|
| Advance Care Planning | 1 | 2015 | 15 | 0.500 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 182 | 0.500 |
Why?
|
| Primates | 1 | 2015 | 111 | 0.480 |
Why?
|
| Adult | 26 | 2024 | 9467 | 0.480 |
Why?
|
| Physicians | 1 | 2016 | 161 | 0.480 |
Why?
|
| Analgesics, Opioid | 4 | 2019 | 262 | 0.480 |
Why?
|
| Smoking Cessation | 3 | 2021 | 195 | 0.470 |
Why?
|
| Smoking | 4 | 2021 | 493 | 0.470 |
Why?
|
| Chlamydia Infections | 3 | 2022 | 11 | 0.460 |
Why?
|
| Vaginosis, Bacterial | 2 | 2024 | 7 | 0.460 |
Why?
|
| Gonorrhea | 3 | 2022 | 11 | 0.460 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 511 | 0.430 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 410 | 0.420 |
Why?
|
| Prevalence | 7 | 2022 | 986 | 0.420 |
Why?
|
| Aged | 16 | 2023 | 10398 | 0.410 |
Why?
|
| Renal Dialysis | 1 | 2015 | 282 | 0.410 |
Why?
|
| Mendelian Randomization Analysis | 2 | 2021 | 15 | 0.400 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 759 | 0.390 |
Why?
|
| Patient Transfer | 3 | 2016 | 44 | 0.390 |
Why?
|
| Middle Aged | 22 | 2022 | 11949 | 0.390 |
Why?
|
| United States | 12 | 2023 | 3983 | 0.380 |
Why?
|
| Alabama | 7 | 2023 | 42 | 0.360 |
Why?
|
| Risk Assessment | 6 | 2019 | 1447 | 0.360 |
Why?
|
| West Virginia | 7 | 2017 | 15 | 0.340 |
Why?
|
| Aged, 80 and over | 7 | 2021 | 4050 | 0.330 |
Why?
|
| Patient Compliance | 2 | 2022 | 227 | 0.330 |
Why?
|
| Risk Factors | 10 | 2022 | 3876 | 0.320 |
Why?
|
| Computer Simulation | 4 | 2023 | 220 | 0.310 |
Why?
|
| Retrospective Studies | 9 | 2023 | 3514 | 0.310 |
Why?
|
| Opioid-Related Disorders | 3 | 2019 | 56 | 0.300 |
Why?
|
| Young Adult | 8 | 2024 | 2626 | 0.260 |
Why?
|
| Exercise | 3 | 2023 | 655 | 0.260 |
Why?
|
| Syphilis | 2 | 2022 | 10 | 0.260 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2022 | 1428 | 0.250 |
Why?
|
| Trichomonas Infections | 2 | 2021 | 2 | 0.250 |
Why?
|
| Incidence | 4 | 2022 | 1207 | 0.240 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2024 | 1 | 0.240 |
Why?
|
| Infant, Newborn | 4 | 2016 | 681 | 0.240 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2018 | 171 | 0.240 |
Why?
|
| Seizures | 2 | 2022 | 70 | 0.230 |
Why?
|
| Hypertension | 2 | 2022 | 972 | 0.230 |
Why?
|
| T-Lymphocytes | 2 | 2021 | 128 | 0.230 |
Why?
|
| Overweight | 3 | 2024 | 270 | 0.220 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2023 | 17 | 0.220 |
Why?
|
| Quality of Life | 2 | 2020 | 915 | 0.220 |
Why?
|
| Socioeconomic Factors | 3 | 2023 | 422 | 0.220 |
Why?
|
| Infant | 4 | 2016 | 1076 | 0.220 |
Why?
|
| Models, Statistical | 1 | 2023 | 176 | 0.220 |
Why?
|
| Hallucinogens | 1 | 2022 | 12 | 0.210 |
Why?
|
| Obesity | 5 | 2024 | 1164 | 0.210 |
Why?
|
| Periodontitis | 1 | 2022 | 9 | 0.210 |
Why?
|
| Adolescent | 8 | 2024 | 3571 | 0.210 |
Why?
|
| Restless Legs Syndrome | 1 | 2021 | 2 | 0.200 |
Why?
|
| Cohort Studies | 6 | 2022 | 1832 | 0.200 |
Why?
|
| Parent-Child Relations | 1 | 2022 | 46 | 0.200 |
Why?
|
| Adiposity | 1 | 2023 | 197 | 0.200 |
Why?
|
| Pilot Projects | 5 | 2023 | 536 | 0.200 |
Why?
|
| Telemedicine | 1 | 2023 | 99 | 0.200 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2021 | 53 | 0.190 |
Why?
|
| Antigens, Differentiation | 1 | 2021 | 26 | 0.190 |
Why?
|
| Conversion Disorder | 1 | 2020 | 2 | 0.190 |
Why?
|
| Psychophysiologic Disorders | 1 | 2020 | 6 | 0.190 |
Why?
|
| Primary Health Care | 3 | 2022 | 221 | 0.190 |
Why?
|
| Prospective Studies | 6 | 2024 | 2274 | 0.180 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 74 | 0.180 |
Why?
|
| Lymphocyte Activation | 1 | 2021 | 90 | 0.180 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2020 | 32 | 0.180 |
Why?
|
| Stress, Psychological | 2 | 2021 | 218 | 0.170 |
Why?
|
| Health Services Research | 1 | 2019 | 82 | 0.170 |
Why?
|
| Prescription Drugs | 1 | 2019 | 20 | 0.170 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2019 | 32 | 0.170 |
Why?
|
| Parathyroid Hormone | 1 | 2018 | 41 | 0.160 |
Why?
|
| SEER Program | 1 | 2018 | 36 | 0.160 |
Why?
|
| Minority Groups | 1 | 2018 | 76 | 0.160 |
Why?
|
| Nicotinic Agonists | 1 | 2018 | 40 | 0.160 |
Why?
|
| Narcotic Antagonists | 1 | 2018 | 59 | 0.160 |
Why?
|
| Living Donors | 1 | 2018 | 63 | 0.150 |
Why?
|
| Body Weights and Measures | 1 | 2017 | 23 | 0.150 |
Why?
|
| Weight Loss | 1 | 2021 | 454 | 0.150 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2019 | 121 | 0.150 |
Why?
|
| Mothers | 2 | 2022 | 87 | 0.150 |
Why?
|
| Food Preferences | 1 | 2017 | 37 | 0.150 |
Why?
|
| Viral Load | 3 | 2023 | 70 | 0.150 |
Why?
|
| Diet | 1 | 2020 | 384 | 0.150 |
Why?
|
| Vitamin D | 1 | 2018 | 186 | 0.140 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 459 | 0.140 |
Why?
|
| Homosexuality, Male | 3 | 2022 | 83 | 0.140 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 217 | 0.140 |
Why?
|
| Transportation of Patients | 1 | 2017 | 26 | 0.140 |
Why?
|
| Medicare | 1 | 2018 | 206 | 0.140 |
Why?
|
| Age Factors | 2 | 2017 | 1204 | 0.140 |
Why?
|
| Information Storage and Retrieval | 1 | 2016 | 25 | 0.140 |
Why?
|
| Sports | 1 | 2017 | 35 | 0.140 |
Why?
|
| Interprofessional Relations | 1 | 2016 | 51 | 0.140 |
Why?
|
| Comorbidity | 4 | 2021 | 572 | 0.140 |
Why?
|
| Hospital Mortality | 2 | 2015 | 197 | 0.140 |
Why?
|
| Ohio | 1 | 2016 | 58 | 0.140 |
Why?
|
| Hospitals, Urban | 1 | 2016 | 14 | 0.130 |
Why?
|
| Hospitals, Rural | 1 | 2016 | 12 | 0.130 |
Why?
|
| Nicotine | 1 | 2018 | 171 | 0.130 |
Why?
|
| Triage | 1 | 2016 | 72 | 0.130 |
Why?
|
| Sex Factors | 1 | 2017 | 674 | 0.130 |
Why?
|
| Quality Assurance, Health Care | 1 | 2016 | 74 | 0.130 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2015 | 54 | 0.130 |
Why?
|
| Binomial Distribution | 1 | 2015 | 2 | 0.130 |
Why?
|
| Echocardiography | 1 | 2015 | 157 | 0.130 |
Why?
|
| Likelihood Functions | 1 | 2015 | 48 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 410 | 0.130 |
Why?
|
| Feasibility Studies | 3 | 2023 | 294 | 0.130 |
Why?
|
| Surgical Procedures, Operative | 1 | 2016 | 83 | 0.120 |
Why?
|
| Databases, Factual | 1 | 2016 | 355 | 0.120 |
Why?
|
| Cross-Over Studies | 1 | 2015 | 101 | 0.120 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2015 | 65 | 0.120 |
Why?
|
| Heart Ventricles | 1 | 2015 | 137 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2016 | 169 | 0.120 |
Why?
|
| Sarcolemma | 1 | 2014 | 4 | 0.120 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 188 | 0.120 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2015 | 171 | 0.120 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2014 | 17 | 0.120 |
Why?
|
| Mitochondria, Heart | 1 | 2014 | 17 | 0.120 |
Why?
|
| Fractures, Bone | 1 | 2016 | 157 | 0.120 |
Why?
|
| Malawi | 1 | 2013 | 19 | 0.120 |
Why?
|
| Kidney Transplantation | 1 | 2018 | 518 | 0.120 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2024 | 15 | 0.120 |
Why?
|
| Wounds and Injuries | 1 | 2016 | 267 | 0.110 |
Why?
|
| Stroke | 1 | 2019 | 585 | 0.110 |
Why?
|
| Vagina | 2 | 2024 | 58 | 0.110 |
Why?
|
| Emergency Service, Hospital | 1 | 2017 | 463 | 0.110 |
Why?
|
| Peptide Nucleic Acids | 1 | 2012 | 3 | 0.110 |
Why?
|
| Candidiasis | 1 | 2012 | 4 | 0.110 |
Why?
|
| Candida | 1 | 2012 | 7 | 0.110 |
Why?
|
| Blood Pressure | 1 | 2017 | 859 | 0.110 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2012 | 41 | 0.110 |
Why?
|
| Antifungal Agents | 1 | 2012 | 39 | 0.110 |
Why?
|
| Heterosexuality | 2 | 2022 | 13 | 0.100 |
Why?
|
| Milk, Human | 1 | 2011 | 16 | 0.100 |
Why?
|
| Causality | 2 | 2021 | 39 | 0.100 |
Why?
|
| Models, Genetic | 2 | 2021 | 94 | 0.100 |
Why?
|
| Universities | 2 | 2023 | 150 | 0.090 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 1040 | 0.090 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 1522 | 0.090 |
Why?
|
| Mass Screening | 2 | 2023 | 263 | 0.090 |
Why?
|
| Students | 2 | 2023 | 175 | 0.090 |
Why?
|
| Kidney Failure, Chronic | 1 | 2015 | 541 | 0.090 |
Why?
|
| Body Mass Index | 2 | 2024 | 921 | 0.090 |
Why?
|
| Longitudinal Studies | 2 | 2022 | 786 | 0.080 |
Why?
|
| Pregnancy | 2 | 2024 | 1010 | 0.080 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 2296 | 0.080 |
Why?
|
| Treatment Outcome | 3 | 2019 | 3358 | 0.070 |
Why?
|
| Animals | 2 | 2015 | 7694 | 0.070 |
Why?
|
| Registries | 2 | 2018 | 300 | 0.070 |
Why?
|
| Logistic Models | 2 | 2019 | 788 | 0.070 |
Why?
|
| Uganda | 1 | 2024 | 8 | 0.060 |
Why?
|
| Fertilization | 1 | 2024 | 6 | 0.060 |
Why?
|
| Gardnerella | 1 | 2024 | 1 | 0.060 |
Why?
|
| Microbial Interactions | 1 | 2024 | 1 | 0.060 |
Why?
|
| Prevotella | 1 | 2024 | 8 | 0.060 |
Why?
|
| Poisson Distribution | 1 | 2023 | 17 | 0.060 |
Why?
|
| Cameroon | 1 | 2023 | 4 | 0.060 |
Why?
|
| Weight Gain | 1 | 2024 | 114 | 0.060 |
Why?
|
| Educational Status | 1 | 2023 | 177 | 0.050 |
Why?
|
| Testosterone | 1 | 2023 | 54 | 0.050 |
Why?
|
| Stavudine | 1 | 2022 | 1 | 0.050 |
Why?
|
| Ritonavir | 1 | 2022 | 3 | 0.050 |
Why?
|
| Integrase Inhibitors | 1 | 2022 | 1 | 0.050 |
Why?
|
| Alkynes | 1 | 2022 | 2 | 0.050 |
Why?
|
| Benzoxazines | 1 | 2022 | 21 | 0.050 |
Why?
|
| Schools | 1 | 2023 | 65 | 0.050 |
Why?
|
| Child | 2 | 2022 | 2472 | 0.050 |
Why?
|
| Cyclopropanes | 1 | 2022 | 20 | 0.050 |
Why?
|
| Ambulatory Care Facilities | 1 | 2023 | 83 | 0.050 |
Why?
|
| Food Supply | 1 | 2023 | 62 | 0.050 |
Why?
|
| Social Support | 1 | 2023 | 180 | 0.050 |
Why?
|
| Sexual Partners | 1 | 2022 | 35 | 0.050 |
Why?
|
| Length of Stay | 2 | 2014 | 315 | 0.050 |
Why?
|
| Antigens, Viral | 1 | 2021 | 21 | 0.050 |
Why?
|
| Immunity, Cellular | 1 | 2021 | 22 | 0.050 |
Why?
|
| Immunity | 1 | 2021 | 22 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 60 | 0.050 |
Why?
|
| Glucose | 1 | 2022 | 177 | 0.050 |
Why?
|
| Lipids | 1 | 2022 | 226 | 0.050 |
Why?
|
| Sexual Behavior | 1 | 2021 | 106 | 0.050 |
Why?
|
| Sleep Deprivation | 1 | 2020 | 9 | 0.050 |
Why?
|
| Motor Activity | 1 | 2023 | 327 | 0.050 |
Why?
|
| Internal-External Control | 1 | 2020 | 17 | 0.050 |
Why?
|
| Behavior Therapy | 1 | 2021 | 102 | 0.050 |
Why?
|
| Linear Models | 1 | 2021 | 454 | 0.050 |
Why?
|
| Conditioning, Classical | 1 | 2020 | 26 | 0.050 |
Why?
|
| Parents | 1 | 2022 | 150 | 0.050 |
Why?
|
| Safety | 1 | 2020 | 78 | 0.050 |
Why?
|
| Attention | 1 | 2020 | 83 | 0.040 |
Why?
|
| Sickness Impact Profile | 1 | 2020 | 37 | 0.040 |
Why?
|
| Self Concept | 1 | 2020 | 42 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2020 | 70 | 0.040 |
Why?
|
| Walking | 1 | 2020 | 204 | 0.040 |
Why?
|
| Time Factors | 2 | 2017 | 2181 | 0.040 |
Why?
|
| Selection Bias | 1 | 2019 | 14 | 0.040 |
Why?
|
| Antihypertensive Agents | 1 | 2022 | 362 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2021 | 911 | 0.040 |
Why?
|
| Physical Fitness | 1 | 2020 | 127 | 0.040 |
Why?
|
| Minority Health | 1 | 2018 | 8 | 0.040 |
Why?
|
| Marijuana Smoking | 1 | 2019 | 39 | 0.040 |
Why?
|
| HIV | 1 | 2018 | 24 | 0.040 |
Why?
|
| Carbon Monoxide | 1 | 2018 | 9 | 0.040 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2018 | 29 | 0.040 |
Why?
|
| Algorithms | 1 | 2021 | 497 | 0.040 |
Why?
|
| Bone and Bones | 1 | 2018 | 89 | 0.040 |
Why?
|
| Accidents, Traffic | 1 | 2020 | 195 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2019 | 124 | 0.040 |
Why?
|
| Vitamin D Deficiency | 1 | 2018 | 93 | 0.040 |
Why?
|
| Personal Autonomy | 1 | 2017 | 10 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2019 | 480 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 696 | 0.040 |
Why?
|
| Bone Density | 1 | 2018 | 186 | 0.040 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2017 | 99 | 0.040 |
Why?
|
| Observation | 1 | 2016 | 25 | 0.030 |
Why?
|
| Health Status | 1 | 2018 | 402 | 0.030 |
Why?
|
| Cardiac Output | 1 | 2015 | 36 | 0.030 |
Why?
|
| Adaptation, Psychological | 1 | 2017 | 134 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2016 | 150 | 0.030 |
Why?
|
| Health Behavior | 1 | 2017 | 229 | 0.030 |
Why?
|
| Systole | 1 | 2015 | 100 | 0.030 |
Why?
|
| Diastole | 1 | 2015 | 100 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2017 | 370 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2016 | 183 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 353 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 325 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2016 | 187 | 0.030 |
Why?
|
| Emergency Medical Services | 1 | 2017 | 165 | 0.030 |
Why?
|
| Cell Respiration | 1 | 2014 | 22 | 0.030 |
Why?
|
| Body Height | 1 | 2014 | 35 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 877 | 0.030 |
Why?
|
| Injury Severity Score | 1 | 2014 | 120 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2016 | 496 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2015 | 339 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2016 | 1281 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2012 | 187 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2014 | 846 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2012 | 101 | 0.020 |
Why?
|
| Mice | 1 | 2015 | 2524 | 0.020 |
Why?
|
| Prognosis | 1 | 2011 | 1523 | 0.020 |
Why?
|